HYDERABAD, India /PRNewswire/ --
Hetero
Group, one of India's leading generic pharmaceutical companies and
one of the world's largest global producer of anti-retroviral drugs
for HIV/AIDS treatment, today announces the successful launch of
its biosimilar 'Rituximab' under the brand
name MABALL[TM] in India. It will be marketed and distributed by
Hetero Healthcare Limited, a group company of Hetero.
The
launch of biosimilar Rituximab will provide a much needed access to
patients in India suffering with Non-Hodgkin Lymphoma (NHL) and
Chronic Lymphocytic Leukaemia (CLL). Rituximab is recommended as
the first-line treatment for NHL and is available in a single dose
vial with two strengths - 100mg/10ml and 500mg/50ml.
Commenting on the launch of the product, Dr
Bandi Parthasaradhi Reddy,
CMD, Hetero Group said: "The launch of MABALL
strengthens Hetero's position in the biosimilar market, and has
enabled the company to join select biotech companies with the
capability to develop, manufacture and commercialize complex
monoclonal antibodies (MAB's)."
He
further added, "Biosimilars is one of the key strategic business
areas for Hetero. We have invested in biosimilars and will
introduce more biosimilar MAB's in the future. We also have plans
to introduce affordable biosimilar Rituximab into key markets
outside India through our partners."
Hetero's Rituximab is a biosimilar version of Roche's Rituximab.
Rituximab is a monoclonal antibody used alone or with other drugs
to treat Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukaemia and
other indications such as Rheumatoid Arthritis.
About
Hetero
Hetero
is one of India's leading generic pharmaceutical companies and
is one of the world's largest global producer of anti-retroviral
drugs for the treatment of HIV/AIDS. Established by
Dr. B.P.S. Reddy in 1993, Hetero is in the business of
development, manufacturing and marketing of drug intermediates,
active pharmaceutical ingredients (APIs), and finished dosages.
Hetero is the largest privately-held pharmaceutical company and is
one of the top 10 pharmaceutical companies in India with an annual turnover of
US $1.2 billion. Hetero has over 25 state-of-the-art
manufacturing facilities which has been approved by various
regulatory authorities like US FDA, EU, WHO etc. With over 200
products in its portfolio across various therapeutic areas, Hetero
has a strong global presence in over 120 countries and focuses on
making affordable medicines accessible to patients worldwide. For
more information, please visit http://www.heteroworld.com
Media
Contact:
Jeyasingh Balakrishnan
Corporate Communications
Hetero Group
Contact: +91-9989626541/ [email protected]
Source: Hetero Group